A 2-hour-old preterm neonate (32 weeks) born to a mother with prolonged rupture of membranes presents with severe respiratory distress (RR 70/min, grunting, intercostal retractions, APGAR 5 at 1 minute). Chest X-ray shows ground-glass appearance consistent with respiratory distress syndrome. What is the drug of choice for immediate treatment?

## Respiratory Distress Syndrome (RDS) in Preterm Neonates: Surfactant Therapy ### Clinical Context This preterm neonate (32 weeks) with RDS (ground-glass infiltrates on CXR, severe respiratory distress) requires immediate surfactant replacement. RDS is caused by surfactant deficiency in immature lungs, leading to increased surface tension, alveolar collapse, and ventilation-perfusion mismatch. ### Drug of Choice: Poractant Alfa (Pulmonary Surfactant) **Key Point:** Exogenous surfactant (poractant alfa, beractant, calfactant) is the gold standard first-line therapy for RDS in preterm neonates. It must be administered within the first few hours of life for maximum efficacy. **High-Yield:** Surfactant therapy reduces mortality by ~40% and incidence of pneumothorax and pulmonary interstitial emphysema (PIE) by ~50% in preterm infants with RDS. ### Surfactant Preparations Available | Preparation | Type | Dose | Route | Notes | | --- | --- | --- | --- | --- | | **Poractant alfa** | Natural (porcine) | 2.5 mg/kg initially, then 1.25 mg/kg at 12 & 24 hrs | Intratracheal | Most potent; preferred first-line | | Beractant | Natural (bovine) | 4 mg/kg as single dose, repeat × 3 | Intratracheal | Requires multiple doses | | Calfactant | Natural (calf) | 3 mg/kg, repeat × 2 | Intratracheal | Rapid onset | | Lucinactant | Synthetic | 5.8 mg/kg | Intratracheal | Less effective than natural surfactants | **Clinical Pearl:** Poractant alfa is the most potent surfactant preparation and requires the lowest total dose (2.5 mg/kg initially vs. 4 mg/kg for beractant), making it the preferred choice in many centers. It is administered intratracheally via an endotracheal tube. ### Mechanism of Action 1. Reduces surface tension at air-liquid interface in alveoli 2. Increases lung compliance and functional residual capacity (FRC) 3. Prevents alveolar collapse during expiration 4. Improves oxygenation and ventilation within minutes ### Timing & Administration - **Timing:** Within 1–2 hours of birth (earlier = better outcomes) - **Route:** Intratracheal (via endotracheal tube) - **Ventilation:** Continue mechanical ventilation; may need to reduce ventilator settings as compliance improves - **Repeat dosing:** Based on clinical response and residual respiratory distress **Warning:** Do NOT confuse surfactant with methylxanthines or doxapram — these are respiratory stimulants used for apnea of prematurity, NOT for RDS. Surfactant is a replacement therapy; methylxanthines are adjunctive. ### Comparison: RDS Medications vs. Apnea of Prematurity Medications | Condition | Drug | Mechanism | Indication | | --- | --- | --- | --- | | **RDS (surfactant deficiency)** | **Poractant alfa** | Replaces deficient surfactant | Acute RDS in preterm infants | | Apnea of prematurity | Caffeine citrate | CNS respiratory stimulant | Recurrent apneic episodes | | Apnea of prematurity | Theophylline | Methylxanthine (less used now) | Apnea prophylaxis | | Apnea of prematurity | Doxapram | Respiratory stimulant | Severe apnea refractory to caffeine | **High-Yield Mnemonic:** **RESCUE** for surfactant indications in RDS: - **R**espiratory distress (clinical signs: grunting, retractions, tachypnea) - **E**arly administration (within 2 hours of birth) - **S**evere hypoxemia (PaO~2~ <60 mmHg on supplemental O~2~) - **C**hest X-ray findings (ground-glass, air bronchograms) - **U**se intratracheal route - **E**xogenous surfactant (poractant alfa preferred) ### Antenatal Corticosteroids: Synergistic Benefit **Clinical Pearl:** Maternal antenatal corticosteroids (betamethasone, dexamethasone) given 24 hours to 7 days before preterm delivery significantly enhance endogenous surfactant production and further reduce RDS severity. This neonate should have received antenatal steroids if delivery was anticipated. ### Algorithm: RDS Management ```mermaid flowchart TD A[Preterm neonate<br/>with respiratory distress]:::outcome --> B{Clinical signs + CXR<br/>consistent with RDS?}:::decision B -->|Yes| C[Intubate and ventilate]:::action C --> D[Administer surfactant<br/>Poractant alfa 2.5 mg/kg IT]:::action D --> E[Monitor response<br/>Improve oxygenation?]:::decision E -->|Yes| F[Wean ventilator settings]:::action E -->|No| G[Repeat surfactant dose<br/>at 12 & 24 hrs]:::action F --> H[Supportive care<br/>Fluid, nutrition, monitoring]:::action G --> I[Reassess clinical status]:::action I --> J[Recovery or complications?]:::decision J -->|Uncomplicated| K[Gradual weaning]:::action J -->|Complications| L[Manage BPD, IVH, NEC]:::action ``` [cite:Textbook of Neonatal Resuscitation 8e, American Academy of Pediatrics; Harrison 21e Ch 173]